Table 6.

Titers and Immune Function by HSCT in Participants Vaccinated for HPV

	HSCT=No (N=10)	HSCT=Yes (N=14)	P
HPV Type	Median (IQR)	Median (IQR)
HPV6 (AU/ml)	179.5 (120.8–296.8)	27.0 (17.1–98.2)	0.030
HPV11 (AU/ml)	262.6 (155.3–363.5)	27.8 (20.7–46.1)	0.003
HPV16 (IU/ml)	683.2 (446.3–1238.3)	100.3 (49.0–693.2)	0.018
HPV18 (IU/ml)	198.5 (65.4–477.9)	26.2 (3.7–56.1)	<0.001
Time Variable	Median (IQR)	Median (IQR)
Years from HSCT to vaccination	-	5.0 (3.0–13.0)	-
Years from vaccination to blood draw	2.0 (1.0–3.0)	3.0 (1.0–5.0)	0.57
Vaccination	N (%)	N (%)
# of HPV Vaccine Doses			0.54
<3 shots	2 (22%)	1 (7%)
3 shots	7 (78%)	13 (93%)
Immune Function	N (%)	N (%)
Total B Cell percent (%)			0.003
Low	5 (63%)	0 (0%)
Normal/High	3 (38%)	13 (100%)
Total Memory B Cells (%)			0.52
Low	0 (0%)	2 (15%)
Normal/High	7 (100%)	11 (85%)
CD4 Absolute
Low	2 (20%)	1 (7%)	0.55
Normal/High	8 (80%)	13 (93%)
IgG (mg/dL)			1.00
Low	2 (20%)	2 (17%)
Normal/High	8 (80%)	10 (83%)
Diphtheria (IU/mL)			1.00
Negative	0 (0%)	1 (8%)
Positive	9 (100%)	12 (92%)
Tetanus (IU/mL)			1.00
Negative	0 (0%)	1 (8%)
Positive	9 (100%)	12 (92%)

Note: Data are shown as median (IQR) and compared using Wilcoxon rank sum test, or as frequency (%) and compared using Fisher’s exact test. HSCT, hematopoietic stem cell transplant. IU, international units, AU, arbitrary units. Tetanus and diphtheria vaccinations were only included if they were given post-HSCT.